Search Results
Oct 15, 2025, 11:54 ET Electronic Grade SiH₄ Silane Gas Market to Reach $5.36B by 2031, Driven by Semiconductors & Solar | Valuates Reports
market size of Electrolytic Manganese Dioxide (EMD) was estimated to be worth USD 966 Million and is forecast to reach approximately USD 1522 Million by 2031 with a CAGR of 6.8% during the forecast
More news about: Valuates Reports
Oct 14, 2025, 16:15 ET Pacific Harbor Line Expands Sustainability Efforts with Remora Partnership
locomotives and then a conversion to renewable diesel fuel which cut CO₂ emissions by some 70 percent. PHL also operated a zero emission (ZE) EMD® Joule battery-electric locomotive from Progress Rail in test service, and it currently operates a Tier 4 locomotive. The
More news about: Pacific Harbor Line
Oct 07, 2025, 20:15 ET CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
transplantation (ASCT), and 5 (25%) had relapsed after CAR T-cell therapies targeting BCMA or BCMA/CD19. Four (20%) patients had extramedullary disease (EMD), 14 (70%) had ≥1 high-risk cytogenetics and 19 (95%) had a Revised International Staging System (R-ISS) 2 or 3 disease at baseline.
More news about: CARsgen Therapeutics
Oct 07, 2025, 08:28 ET Lupus Research Alliance Invites Communities to Walk with Us to Cure Lupus Fall Season
Football League Foundation, Northwell Health, AstraZeneca, Bristol Myers Squibb, Cushman & Wakefield, MVP Worldwide Logistics, NYU Langone Health, EMD Serono, KPMG, RPW Group Inc., iHeart Media and WCBS/WLNY. About Lupus
More news about: Lupus Research Alliance
Sep 18, 2025, 21:39 ET 2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
least three prior lines of therapy and with progressive disease after the last line of therapy were enrolled. And patients with extramedullary disease (EMD) or prior exposure to anti-BCMA CAR-T therapy were included.
More news about: IASO Bio
Sep 10, 2025, 17:31 ET TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight
including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong
More news about: DelveInsight Business Research, LLP
Aug 25, 2025, 06:19 ET Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
(ORR) similar to CAR-T treatment. Notably, promising efficacy was also observed in the subgroup of patients with difficult-to-treat extramedullary (EMD) plasmacytomas. Furthermore, the minimal residual disease (MRD) negativity rate was also significantly higher than with current standard of care. The
More news about: Leads Biolabs
Aug 21, 2025, 18:08 ET NORD's 2025 Rare Diseases & Orphan Products Breakthrough Summit to Spotlight CEOs, Investors, and Regulatory Leaders Driving Innovation
together leaders who are redefining what is possible, featuring conversations with: Miguel Fernández Alcalde, President, EMD Serono Christophe Arbet-Engels, MD, PhD, Chief Medical Officer, X4 PharmaceuticalsCatherine
More news about: National Organization for Rare Disorders (NORD®)
Aug 06, 2025, 17:46 ET Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight
UroGen Pharma, Tyra Biosciences, Taiho Oncology, UroGen Pharma, Astellas Pharma, Johnson & Johnson Innovative Medicine, Merck, EMD Serono (a business of Merck, Darmstadt, Germany), Pfizer, Bristol-Myers Squibb, and others
More news about: DelveInsight Business Research, LLP
Aug 04, 2025, 06:00 ET Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results
planning is underway, and I'm pleased to share that Chris Ross, SVP of Global Operations, will lead this effort. Chris and I successfully partnered on the EMD Millipore–Sigma-Aldrich integration, and I'm confident in his leadership to deliver strong results once again." A description and reconciliation
More news about: Waters Corporation
Aug 01, 2025, 01:00 ET Global New Material International schließt transformative Übernahme des Surface-Solutions-Geschäfts von Merck ab und beschleunigt damit seine globale Expansion
die USA und Kanada, wo die Geschäftsbereiche von Merck als MilliporeSigma im Bereich Life Sciences, EMD Serono im Bereich Healthcare und EMD Electronics im Bereich Electronics tätig sind. Foto -
More news about: Global New Material International Holdings Limited
Jul 31, 2025, 16:05 ET Rocket Companies Announces Second Quarter 2025 Results
clients.In Q2, Rocket Mortgage launched an agentic AI tool within the Rocket Logic loan origination system to handle reviewing earnest money deposits (EMD), the funds buyers provide to show commitment in a home purchase. Previously, tracking and validating EMDs involved significant manual work; now, agentic
More news about: Rocket Companies, Inc.
Jul 30, 2025, 17:31 ET Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight
the key osteosarcoma companies, including Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics, among others.
More news about: DelveInsight Business Research, LLP
Jul 23, 2025, 09:00 ET Helio Genomics Appoints Dr Bharat Tewarie As Chief Executive Officer To Lead The Next Phase Of Growth In AI-Powered Cancer Detection
leadership roles across BioPharma, Digital Health, Diagnostics and Medical Devices. He has held senior positions at UCB (EVP & CMO), Merck KGaA, EMD Serono, Roche, and Boehringer Ingelheim, and served as CEO of startups including Neurocast and Prana BioSciences. Beyond his operational and commercial
More news about: Helio Genomics
Jul 09, 2025, 03:00 ET Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
industry experience, including a track record of more than a dozen development candidates. His background includes over a decade of discovery leadership at EMD Serono, where he led medicinal chemistry. In his role as Entrepreneur-in-Residence (EIR) at M Ventures, he led the scientific efforts of and supported
More news about: Actithera
Jun 18, 2025, 08:00 ET Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program
Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with
More news about: Emyria Ltd
Jun 17, 2025, 08:00 ET Valeris™ Expands Strategic Infrastructure with Launch of Transformation Office
Obregon, who brings deep expertise in market access, pricing, contracting, and operational execution. Laura previously held leadership roles at EMD Serono across U.S. Oncology and Market Access and Patient Solutions, where she led high-impact strategic initiatives and enterprise transformation efforts.
More news about: Valeris
Jun 17, 2025, 07:00 ET Announcing The World Fertility Awards: Celebrating Global Change Agents Advancing Fertility Awareness, Inclusion, and Innovation
[email protected]. Initial sponsors include US Fertility, LendingClub, LabCorp, IVI RMA, EMD Serono Canada, among others. About Pregnantish Inc.
More news about: Pregnantish
Jun 15, 2025, 03:15 ET Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
have true extramedullary disease (EMD). EMD is defined as soft tissue/organ-associated plasmacytomas with no contact to bony structures as per International Myeloma Working Group (IMWG) criteria.1 RedirecTT-1 is the largest study dedicated to patients with EMD to date. These data were featured
More news about: Johnson & Johnson
Jun 11, 2025, 07:00 ET Simtra BioPharma Solutions and MilliporeSigma Announce Strategic Alliance for Antibody Drug Conjugates Drug Substance and Drug Product Manufacturing Services
where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's
More news about: Simtra BioPharma Solutions
Jun 10, 2025, 09:05 ET Kindbody Names David Stern as Chief Executive Officer to Lead Next Stage of Growth
also held senior executive roles at Merck Serono, where he served as Senior Vice President and Head of the Global Fertility Business Franchise, and at EMD Serono as Executive Vice President of Endocrinology within their biopharmaceutical division. His extensive experience further includes strategic leadership
More news about: Kindbody
Jun 09, 2025, 17:31 ET HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight
the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis,
More news about: DelveInsight Business Research, LLP